Psychopharmacology

, Volume 216, Issue 3, pp 379–387 | Cite as

Aripiprazole maintenance increases smoked cocaine self-administration in humans

Original Investigation

Abstract

Rationale

Partial dopamine receptor agonists have been proposed as candidate pharmacotherapies for cocaine dependence.

Objective

This 42-day, within-subject, human laboratory study assessed how maintenance on aripiprazole, a partial D2 receptor agonist, influenced smoked cocaine self-administration, cardiovascular measures, subjective effects, and cocaine craving in nontreatment-seeking, cocaine-dependent volunteers.

Methods

In order to achieve steady-state concentrations, participants (n = 8 men) were administered placebo and aripiprazole (15 mg/day) capsules in counter-balanced order for 21 days. A smoked cocaine dose–response curve (0, 12, 25, 50 mg) was determined twice under placebo and aripiprazole maintenance. Sessions comprised a “sample” trial, when participants smoked the cocaine dose available that session, and five choice trials, when they responded on a progressive-ratio schedule of reinforcement to receive the cocaine dose or receive $5.00.

Results

Cocaine’s reinforcing, subjective, and cardiovascular effects were dose-dependent. Aripiprazole significantly increased cocaine (12, 25 mg) self-administration. Following a single administration of cocaine (25 mg), aripiprazole decreased ratings of how much participants would pay for that dose. Following repeated cocaine (50 mg) self-administration, aripiprazole decreased ratings of cocaine quality, craving, and good drug effect as compared to placebo.

Conclusions

These data suggest that aripiprazole may have increased self-administration to compensate for a blunted subjective cocaine effect. Overall, the findings do not suggest aripiprazole would be useful for treating cocaine dependence.

Keywords

Addiction Antipsychotic Cocaine 

Notes

Acknowledgments

The authors would also like to thank the nurses, physicians, and research assistants working in the Marian W. Fischman Cocaine Research Laboratory, and appreciate the contributions of their fellow investigators: Drs. Carl L. Hart, Suzanne Vosburg, Nehal Vadhan, Suzette Evans, and Stephanie Collins Reed.

Financial disclosures

Dr. Haney received consultant fees from Celtic Pharmaceuticals in 2007. Dr. Foltin currently receives research support for an investigator-initiated protocol from Aztra Zeneca. Dr. Rubin reported no biomedical financial interests or potential conflicts of interest. This research was supported by both NIDA (DA10755/Haney; DA006234/Foltin) and funding from Bristol-Meyers Squibb. Participants resided on the Irving Institute for Clinical and Translational Research of The New York-Presbyterian Medical Center, supported by Grant No. MOI-RR-00645 from the National Institutes of Health.

References

  1. Amato L, Minozzi S, Pani PP, Davoli M (2010) Antipsychotic medications for cocaine dependence (Review). Cochrane Libr 3:1–37Google Scholar
  2. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF (2005) Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25:363–366PubMedCrossRefGoogle Scholar
  3. Bergman J (2008) Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D2 partial agonist aripiprazole (Abilify®). Exp Clin Psychopharmacol 16:475–483PubMedCrossRefGoogle Scholar
  4. Berman RM, Marcus RN, Swanink R, McQuade R, Carson WH, Corey-Lisle PK, Khan A (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatr 68:843–853CrossRefGoogle Scholar
  5. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L (2005) Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatr 66:756–760CrossRefGoogle Scholar
  6. Cahill K, Stead L, Lancaster T (2009) A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2:119–135CrossRefGoogle Scholar
  7. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatr 63:210–218PubMedCrossRefGoogle Scholar
  8. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz LR, Thase ME, Weiss RD, Gastfriend DR, Woody GE, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT (1999) Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatr 56:493–502PubMedCrossRefGoogle Scholar
  9. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW (2008) A meta-analytic review of psychosocial interventions for substance abuse use disorders. Am J Psychiatr 165:179–187PubMedCrossRefGoogle Scholar
  10. Evans SM, Haney M, Foltin RW (2002) The effects of smoked cocaine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl) 159:397–406Google Scholar
  11. Feltenstein MW, Altar CA, See RE (2007) Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatr 61:582–590CrossRefGoogle Scholar
  12. Feltenstein MW, Do PH, See RE (2009) Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse. Psychopharmacology 207:401–411PubMedCrossRefGoogle Scholar
  13. Grabowski JA, Shearer J, Merrill J, Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439–1464PubMedCrossRefGoogle Scholar
  14. Haney M, Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:403–419PubMedCrossRefGoogle Scholar
  15. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 155:330–337PubMedCrossRefGoogle Scholar
  16. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW (2010) Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatr 67:59–65CrossRefGoogle Scholar
  17. Howell LL, Kimmel HL (2008) Monoamine transporters and psychostimulant addition. Biochem Pharmacol 75:196–217PubMedCrossRefGoogle Scholar
  18. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7-(4-[4-(2, 3-dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro−2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137–143PubMedGoogle Scholar
  19. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290–1297PubMedCrossRefGoogle Scholar
  20. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingentio G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatr 160:1651–1658PubMedCrossRefGoogle Scholar
  21. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612–627PubMedCrossRefGoogle Scholar
  22. Lieberman JA (2004) Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251–267PubMedCrossRefGoogle Scholar
  23. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR (2005) Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology 30:2103–2114PubMedCrossRefGoogle Scholar
  24. Lile JA, Stoops WW, Hays LR, Rush CR (2008) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse 34:721–729PubMedCrossRefGoogle Scholar
  25. Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR (2011). Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. J Psychopharmacology October 15 (in press)Google Scholar
  26. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatr 164:1411–1417PubMedCrossRefGoogle Scholar
  27. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatr 66:1116–1123PubMedCrossRefGoogle Scholar
  28. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M (2007) Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatr 164:622–629PubMedCrossRefGoogle Scholar
  29. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, Slifstein M, Van Heertum R, Kleber HD (2009) Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatr 166:1170–1177PubMedCrossRefGoogle Scholar
  30. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1–93PubMedGoogle Scholar
  31. Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R, Palamar J, Halkitis PN, Mojisak J, Anderson A, Li SH, Elkashef A (2008) Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 11:1037–1045PubMedCrossRefGoogle Scholar
  32. Owen L, Sikich RN, Marcus et al (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540PubMedCrossRefGoogle Scholar
  33. Platt DM, Rodefer JS, Rowlett JK (2002) Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology (Berl) 166:298–305Google Scholar
  34. Pulvirenti L, Koob GF (2002) Being partial to psychostimulant addiction therapy. Trends in Pharmacol Sci 23:151–153CrossRefGoogle Scholar
  35. Sørensen G, Sager TN, Petersen JH, Brennum LT, Thøgersen P, Hee Bengtsen C, Thomsen M, Wörtwein G, Fink-Jensen A, Woldbye DP (2008) Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology 199:37–46PubMedCrossRefGoogle Scholar
  36. Stoops WW (2006) Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 4:413–421Google Scholar
  37. Stoops WW, Lile JA, Lofwall MR, Rush CR (2007) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 33:769–776PubMedCrossRefGoogle Scholar
  38. Thomsen M, Fink-Jensen A, Woldbye DP, Wörtwein G, Sager TN, Holm R, Pepe LM, Caine SB (2008) Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacology 201:43–53PubMedCrossRefGoogle Scholar
  39. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatr 164:160–162PubMedCrossRefGoogle Scholar
  40. Vocci FJ, Ling WW (2005) Medications development: successes and challenges. Pharmacol Ther 108:94–108PubMedCrossRefGoogle Scholar
  41. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Pappas N, Hitzermann R, Shea CE (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827–830PubMedCrossRefGoogle Scholar
  42. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatr 9:557–569CrossRefGoogle Scholar
  43. Wee S, Wang Z, Woolverton WL, Pulvirenti L, Koob GF (2007) Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32:2238–2247PubMedCrossRefGoogle Scholar
  44. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248–259PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Margaret Haney
    • 1
  • Eric Rubin
    • 1
  • Richard W. Foltin
    • 1
  1. 1.Department of Psychiatry, College of Physicians and Surgeons of Columbia University and the Division on Substance AbuseNew York State Psychiatric InstituteNew YorkUSA

Personalised recommendations